GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CellaVision AB (LTS:0MR5) » Definitions » Debt-to-Equity

CellaVision AB (LTS:0MR5) Debt-to-Equity : 0.14 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is CellaVision AB Debt-to-Equity?

CellaVision AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr82.0 Mil. CellaVision AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr25.5 Mil. CellaVision AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr758.8 Mil. CellaVision AB's debt to equity for the quarter that ended in Mar. 2024 was 0.14.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CellaVision AB's Debt-to-Equity or its related term are showing as below:

LTS:0MR5' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.09   Med: 0.2   Max: 0.5
Current: 0.14

During the past 13 years, the highest Debt-to-Equity Ratio of CellaVision AB was 0.50. The lowest was 0.09. And the median was 0.20.

LTS:0MR5's Debt-to-Equity is ranked better than
61.02% of 703 companies
in the Medical Devices & Instruments industry
Industry Median: 0.22 vs LTS:0MR5: 0.14

CellaVision AB Debt-to-Equity Historical Data

The historical data trend for CellaVision AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellaVision AB Debt-to-Equity Chart

CellaVision AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.31 0.25 0.16 0.09

CellaVision AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.20 0.18 0.09 0.14

Competitive Comparison of CellaVision AB's Debt-to-Equity

For the Medical Devices subindustry, CellaVision AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CellaVision AB's Debt-to-Equity falls into.



CellaVision AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CellaVision AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

CellaVision AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellaVision AB  (LTS:0MR5) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


CellaVision AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CellaVision AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CellaVision AB (LTS:0MR5) Business Description

Traded in Other Exchanges
Address
Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in the business of supplying digital solutions for blood and body fluid analysis. Its solutions are based on digital image analysis technology, artificial intelligence, and information technology. The firm's product portfolio consists of CellaVision peripheral blood application, CellaVision advanced RBC application, and CellaVision remote review software. Its customers include mainly large hospital laboratories and commercial laboratories in North America, Europe and China, and Japan. The company derives the majority of its revenue from the sale of analyzers.

CellaVision AB (LTS:0MR5) Headlines

No Headlines